• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michael.dickinson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree (Honours)
The University of Western Australia
ORCID

0000-0002-1492-5966

Prof Michael Dickinson

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

117 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.
    DOI: 10.1182/bloodadvances.2026020012
  • 2026

    Journal article

    Web-Based Cognitive Rehabilitation for Patients With Aggressive Lymphoma With Perceived Cognitive Impairment: A Randomised Pilot Study.
    DOI: 10.1002/pon.70469
  • 2026

    Journal article

    Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
    DOI: 10.1080/10428194.2026.2631102
  • 2026

    Journal article

    Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries
    DOI: 10.1182/blood.2025030872
  • 2026

    Journal article

    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
    DOI: 10.1182/blood.2025032307
  • 2026

    Journal article

    Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era
    DOI: 10.1111/bjh.70451
  • 2019

    Journal article

    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
    DOI: 10.1111/bjh.16069
Michael Dickinson

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    DLBCL tumor microenvironment archetype and CD4 T cell conversion to cytotoxic cells are required for response to glofitamab
    DOI: 10.1182/blood-2025-557
  • 2025

    Journal article

    Glofitamab Combined with Pola-R-CHP or R-CHOP as First Therapy in Younger Patients with High-Risk Large B-Cell Lymphoma: Results from the COALITION Study
    DOI: 10.1200/JCO-25-00481
  • 2025

    Journal article

    440 | GOLDILOX: FIRST EXPERIENCE OF TWO DOSING STRATEGIES OF PIRTOBRUTINIB AND GLOFITAMAB FOR MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH COVALENT BTK INHIBITORS
    DOI: 10.1002/hon.70094_440
  • 2025

    Journal article

    197 | CD4 T CELL RECRUITMENT AND DIFFERENTIATION INTO A CYTOTOXIC PHENOTYPE IS ASSOCIATED WITH THE TREATMENT OF PATIENTS WITH GLOFITAMAB TOGETHER WITH R‐CHOP OR POLA‐R‐CHP
    DOI: 10.1002/hon.70094_197

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224